Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-27T22:30:18.093Z Has data issue: false hasContentIssue false
  • English
  • Français

Histological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland

Published online by Cambridge University Press:  29 June 2007

Masashi Suzuki ,
Issei Ichimiya ,
Futoshi Matsushita  and
Goro Mogi
Masashi Suzuki
Affiliation:
Department of Otolaryngology, Oita Medical University, Oita, Japan.
Issei Ichimiya
Affiliation:
Department of Otolaryngology, Oita Medical University, Oita, Japan.
Futoshi Matsushita
Affiliation:
Department of Otolaryngology, Oita Medical University, Oita, Japan.
Goro Mogi*
Affiliation:
Department of Otolaryngology, Oita Medical University, Oita, Japan.
*
Address for correspondence: Goro Mogi, M. D., Department of Otolaryngology, Oita Medical University, 1-1 Idaigaoka, Hasama-machi, Oita 879-5593, Japan. Fax: 097-549-0762
Get access Rights & Permissions [Opens in a new window]

Abstract

Histological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland were analysed. Tumours from 13 patients were classified according to histological grades and immunoreactivity for HEK-2/neu. Surgical resection of the tumour was performed for all patients, and the overall five-year survival rate was 69 per cent. The patients whose histological grades were 1 or 2 showed a 100 per cent five-year survival rate, but no patient with grade 3 survived five years. Also, patients who had tumours that overexpressed HER-2/new had a lower survival rate (25 per cent) than patients with tumours that had weaker immunostaining (89 per cent). We considered tumours classified as grade 3 plus strong HER-2/neu expression to be ‘high malignancy’, and compared them with ‘low malignancy’ tumours that were grade 1 or 2 and had weaker HER-2/new staining. Patients with high malignancy tumours had shorter recurrence-free intervals and shorter overall survival than patients with low malignancy tumours. The overall survival period of the low malignancy cases was much longer than the recurrence-free interval; unlike that in the high malignancy tumour patients. These results suggest that the combination of histological grades and expression of HER-2/neu may be a useful predictor of the prognosis for mucoepidermoid carcinomata.

Keywords

Parotid neoplasmsImmunohistochemistryNeoplasm stagingSurvival rate
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 112 , Issue 10 , October 1998 , pp. 944 - 947
Copyright
Copyright © JLO (1984) Limited 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Batsakis, J. G., Luna, M. A. (1990) Histopathologic grading of salivary gland neoplasms. I. Mucoepidermoid carcinomas. Annals of Otology, Rhinology and Laryngology 99: 835–838.CrossRefGoogle ScholarPubMed
Clode, A. L., Fonseca, I., Santos, J. R., Soares, J. (1991) Mucoepidermoid carcinoma of the salivary glands: a reappraisal of the influence of tumor differentiation on prognosis. Journal of Surgical Oncology 46: 100–106.CrossRefGoogle ScholarPubMed
Healey, W. V., Perzin, K. H., Smith, L. (1970) Mucoepider-moid carcinoma of salivary gland origin. Classification, clinical-pathologic correlation, and results of treatment. Cancer 26: 368–388.3.0.CO;2-K>CrossRefGoogle Scholar
Hetzel, D. J., Wilson, T. O., Keeney, G. L., Roche, P. C., Cha, S. S., Podratz, K. C. (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecologic Oncology 47: 179–185.CrossRefGoogle Scholar
Kernohan, N. M., Blessing, K., King, G., Corbett, I. P., Miller, I. D. (1991) Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. Journal of Pathology 163: 77–80.CrossRefGoogle ScholarPubMed
Press, M. R., Hung, G., Godolphin, W., Slamon, D. J. (1994a) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Research 54: 2771–2777.Google ScholarPubMed
Press, M. F., Pike, M. C., Chazin, V. R.Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W., Sliw-kowski, M., Akita, R., et al. (1993) HER-2/rce expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpres-sion with increased risk of recurrent disease. Cancer Research 53: 4960–4970.Google Scholar
Press, M. F., Pike, M. C., Hung, G., Zhou, J. Y., Ma, Y., George, J., Dietz, B. J., James, W., Slamon, D. J., Batsakis, J. G., et al. (1994b) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Research 54: 5675–5682.Google ScholarPubMed
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., Weinberg, R. A. (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513–516.CrossRefGoogle ScholarPubMed
Shih, C., Padhy, L. C., Murray, M., Weinberg, R. A. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290: 261–264.CrossRefGoogle ScholarPubMed
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.CrossRefGoogle ScholarPubMed
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) Studies of the HER-2/new proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.CrossRefGoogle Scholar
Sugano, S., Mukai, K., Tsuda, H., Hirohashi, S., Furuya, S., Shimosato, Y., Ebihara, S., Takeyama, I. (1992) Immuno-histochemical study of c-erbB-2 oncoprotein overexpression i n human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102: 923–927.CrossRefGoogle Scholar